Related Experiment Video
Updated: Jan 18, 2026
08:07
Personalized Peptide Arrays for Detection of HLA Alloantibodies in Organ Transplantation
Published on: September 6, 2017
10.6K
HPA-1a alloimmunization and pregnancy outcome in a Polish screening program: PREVFNAIT
Guz Katarzyna1, Uhrynowska Małgorzata1, Orzińska Agnieszka1
1Department of Hematological and Transfusion Immunology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
Transfusion
|January 16, 2026
Summary
Fetal/neonatal alloimmune thrombocytopenia (FNAIT) screening in HPA-1a-negative mothers is feasible. Retrospective diagnostics improved detection of FNAIT, including cases with intracranial hemorrhage (ICH) missed by prospective screening.
Area of Science:
- Obstetrics and Gynecology
- Neonatology
- Immunology
Background:
- Fetal/neonatal alloimmune thrombocytopenia (FNAIT) is a significant cause of intracranial hemorrhage (ICH) in newborns.
- It is primarily caused by maternal antibodies to human platelet antigen (HPA)-1a in HPA-1a-negative mothers.
Purpose of the Study:
- To assess the feasibility of antenatal screening for HPA-1a antibodies.
- To investigate the natural history of FNAIT.
- To establish a biobank for HPA-1a-negative pregnancies.
Main Methods:
- Screened 24,236 pregnant women for HPA-1a.
- Used Monoclonal Antibody Immobilization of Platelet Antigens (MAIPA) for prospective antibody testing.
- Employed Luminex bead-based immunoassay (PAKLx) for retrospective analysis in cases of neonatal thrombocytopenia or ICH.
Main Results:
- Detected anti-HPA-1a antibodies in 9.1% of HPA-1a-negative women.
- Diagnosed FNAIT in 32% of alloimmunized pregnancies.
- Retrospective PAKLx identified 3 ICH cases not detected by prospective MAIPA.
Conclusions:
- Antenatal screening for HPA-1 is feasible.
- A comprehensive biobank was successfully established.
- Retrospective diagnostics significantly improved FNAIT detection, including severe cases of ICH.
